Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Cognitive Effects of Aripiprazole in a Broad Range of Schizophrenic Patients
2004-000903-17Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Bristol Myers Squibb. Primary endpoint: Clinical Global Impression – Improvement (CGI-I) at Week 12. Started Jul 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-000903-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000903-17.